Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
about
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside ReviewGlucagon and heart in type 2 diabetes: new perspectivesThe EMPA-REG outcome study: critical appraisal and potential clinical implicationsDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetesSodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidenceSodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metforminEfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusDeciding oral drugs after metformin in type 2 diabetes: An evidence-based approachSLC transporters as therapeutic targets: emerging opportunitiesHeart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 DiabetesSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsPractical combination therapy based on pathophysiology of type 2 diabetesImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureSGLT2 Inhibitors May Predispose to KetoacidosisThe Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart FailureInfluence of Familial Renal Glycosuria Due to Mutations in the SLC5A2 Gene on Changes in Glucose Tolerance over TimeBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisPharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia.Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.Common variation in the sodium/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations.Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusionsEfficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusA randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesGlycemic variability and oxidative stress: a link between diabetes and cardiovascular disease?The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicityEffect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes.Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.Short commentary on empagliflozin and its potential clinical impactLP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2.Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 DiabetesSGLT-2 inhibition and glucagon: Cause for alarm?Proinsulin-producing, hyperglycemia-induced adipose tissue macrophages underlie insulin resistance in high fat-fed diabetic miceEfficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis.Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
P2860
Q24563917-9900CF89-0B23-4302-9FF8-9DDB71DDFBB2Q26738580-C5EBF6F7-C3B1-41E1-802E-8FE3DF642E65Q26748742-1C7ABADD-D9DC-436F-8F55-526459E28978Q26749281-255801D8-A44C-466F-BE6A-34D151B7971AQ26752703-6F1CBAC1-3779-44A8-9F27-97BB073FCA57Q26752815-FCE28D22-5A8D-4B1B-857B-4C9B43484C36Q26782225-3738FB56-35BB-4B9E-9A07-F7B29EE5E16DQ26851797-CAD95E45-C192-43C1-A9A8-ED1B68F7CAAEQ27014726-0EDA0205-CEA3-48B6-AED1-231DE0940E55Q27301948-8C60738A-639E-42C3-B1B7-E9ECB700A9FDQ28072339-B0F55B67-0700-4F73-AE09-554EC0ED354BQ28072765-4D2900D6-38DA-4AA3-8331-D0493B886A9EQ28076530-39DA21CB-E850-4FDB-A34E-212D01120C46Q28080114-7CB73766-C11A-46AD-9AC3-B6C675CA83F7Q28081173-BEA0B76C-4920-4CC2-9EB3-A8EA320368C6Q28082343-F921EB7B-F110-4B45-85FD-2E5EEB1F9E8EQ28552106-4BC5A8F3-AC84-4E81-9DD3-D8E4032E8F8FQ28553482-DAF21B21-E402-43EB-86ED-07900878EC5DQ30250020-0509CD44-FF3D-4802-84FD-075F9F7273AFQ33556240-F84E9EC1-E2BD-4DBA-9BD2-65D06293FF3DQ33626249-513FB9C3-FE70-4160-B676-774A1E34477BQ33638177-E9B87EE2-0DC5-404A-A747-028CA88744BAQ33820904-060F9CEB-C1D8-4A3F-8896-E2B85DB25F71Q33835558-9EB52004-EFFA-427D-8523-6F01D81C905AQ33871321-0977FCB3-DCB4-416B-BC5D-758DD97496BDQ33913060-57CA2437-70A0-4B7B-917C-11191D9B88B2Q34198692-697FEF78-2292-43F8-ABDE-A8E996A950D0Q34486820-37BAC02C-662E-483F-BD4F-AF9ABF41393AQ34524690-D4F37E2E-D808-4729-A9D1-16CADA55E713Q35117192-4A7B43F9-5C75-4CA7-AC97-EB03A0B1F278Q35137042-6637ECD4-D1AB-4044-B0AF-0D4A8EB02F4FQ35157497-0CBE3A7A-F456-4B00-BE8D-12CDCAFC9A00Q35181821-7EAB3CA4-B703-4FF6-9188-05946960BAB2Q35528797-D9DF9236-B711-4A0A-9F68-38E09B73B269Q35664940-7016F7D4-9BB4-4C68-980C-0D4557920444Q35669990-8B7271D9-008F-4ACC-A2FA-263ECD6E3DA7Q35812506-6B71430F-5F99-40AA-8050-A3066824B385Q35879028-9F3312BF-836C-459D-ACAC-C19BAC637487Q35911236-C3BC5359-39CF-4463-A5B2-446BCE641C1CQ35957448-F8031760-19CC-4489-AE3F-747971F39920
P2860
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metabolic response to sodium-g ...... n in type 2 diabetic patients.
@en
Metabolic response to sodium-g ...... n in type 2 diabetic patients.
@nl
type
label
Metabolic response to sodium-g ...... n in type 2 diabetic patients.
@en
Metabolic response to sodium-g ...... n in type 2 diabetic patients.
@nl
prefLabel
Metabolic response to sodium-g ...... n in type 2 diabetic patients.
@en
Metabolic response to sodium-g ...... n in type 2 diabetic patients.
@nl
P2093
P2860
P921
P356
P1476
Metabolic response to sodium-g ...... n in type 2 diabetic patients.
@en
P2093
Andrea Mari
Ele Ferrannini
Hans-Juergen Woerle
Silvia Frascerra
Simona Baldi
Uli C Broedl
P2860
P304
P356
10.1172/JCI72227
P407
P577
2014-01-27T00:00:00Z